Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (3665)	12/2/2002 9:55:40 AM
From: fred hayes	Read Replies (4) \| Respond to of 10345

>>the incorrect scientific assumption has resulted in a six-fold increase in clinical trials which have "singularly failed to show a cure or to convey major benefits to MS patients in addition to subjecting them to an increased morbidity and mortality">> Looks to me like they're saying the interferon approach of Biogen and others is all wet!? I can't reconcile this with the benefits of current treatment, which I thought were indisputable, nor am I sure how to apply this to Antegren. fred